Aprotinin is safe in pediatric patients undergoing cardiac surgery

Journal of Thoracic and Cardiovascular Surgery

Volumn 134, Issue 6, 2007, Pages 1421-1428

  Backer, Carl L ^a   Kelle, Angela M ^a   Stewart, Robert D ^a   Suresh, Sunitha C ^a   Ali, Farah N ^a   Cohn, Richard A ^a   Seshadri, Roopa ^a   Mavroudis, Constantine ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

ACUTE KIDNEY FAILURE; ARTICLE; CARDIOPULMONARY BYPASS; CHILD; CONTROLLED STUDY; DIALYSIS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART SURGERY; HUMAN; LOADING DRUG DOSE; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUROLOGICAL COMPLICATION; PEDIATRICS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; SURGICAL MORTALITY; UNIVARIATE ANALYSIS;

APROTININ; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY FAILURE, ACUTE; MALE; NERVOUS SYSTEM DISEASES; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SERINE PROTEINASE INHIBITORS;

EID: 36148998748     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2007.08.006     Document Type: Article

References (23)

1. Approval of aprotinin [press release]. Washington (DC): US Food and Drug Administration; December 30, 1993. Available at: http://www.fda.gov/bbs/topics/NEWS/NEW00453.html.
2. Levy J.H., Pifarre R., Schaff H.V., et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 92 (1995) 2236-2244
3. Cosgrove III D.M., Heric B., Lytle B.W., et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 54 (1992) 1031-1036
4. Sedrakyan A., Treasure T., and Elefteriades J.A. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 128 (2004) 442-448
5. Kozik D.J., and Tweddell J.S. Characterizing the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 81 suppl (2006) S2347-S2354
6. Hill G.E., Alonso A., Spurzem J.R., Stammers A.H., and Robbins R.A. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 110 (1995) 1658-1662
7. Costello J.M., Backer C.L., de Hoyos A., Binns H.J., and Mavroudis C. Aprotinin reduces operative closure time and blood product use after pediatric bypass. Ann Thorac Surg 75 (2003) 1261-1266
8. D'Errico C.C., Shayevitz J.R., Martindale S.J., Mosca R.S., and Bove E.L. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg 83 (1996) 1193-1199
9. Miller B.E., Tosone S.R., Tam V.K., et al. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg 66 (1998) 535-540
10. Mangano D.T., Tudor I.C., Dietzel C., Multicenter Study of Perioperative Ischemia Research Group, and Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
11. Mangano D.T., Miao Y., Vuylstekc A., et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 297 (2007) 471-479
12. Levy J.H., Ramsay J.G., and Guyton R.A. Aprotinin in cardiac surgery. [letter to the editor]. N Engl J Med 354 (2006) 1953-1957
13. Royston D., van Haaften N., and De Vooght P. Aprotinin; friend or foe?. Eur J Anesthesiol 24 (2007) 6-14
14. Ferguson Jr. T.B. Aprotinin-are there lessons learned?. JAMA 297 (2007) 471-479
15. Jacobs J.P., Mavroudis C., Jacobs M.L., and Joint EACTS-STS Congenital Database Committee. What is operative mortality?. Defining death in a surgical registry database: a report of the STS Congenital Database Taskforce and the Joint EACTS-STS Congenital Database Committee. Ann Thorac Surg 81 (2006) 1937-1941
16. Kincaid E.H., Ashburn D.A., Hoyle J.R., Reichert M.G., Hammon J.W., and Kon N.D. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery?. Ann Thorac Surg 80 (2005) 1388-1393
17. Therneau T.M., and Grambsch P.M. Modeling survival data: extending the Cox model (2000), Springer, New York
18. Liang K.Y., and Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
19. O'Brien SM, Clarke DP, Jacobs JP, et al. Accuracy of the Aristotle basic complexity score for classifying the mortality and morbidity potential of congenital heart surgery procedures. Paper presented at: 43rd Annual Meeting of the Society of Thoracic Surgeons; January 29, 2007; San Diego, Calif.
20. Arnold D.M., Fergusson D.A., Chan A.K., et al. Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of Aprotinin. Anesth Analg 102 (2006) 731-737
21. Skidmore K.L., and Azakie A. Aprotinin and Sevoflurane do not affect renal function during single-ventricle palliative surgery [letter to the editor]. Anesth Analg 103 (2006) 1614-1615
22. Jaquiss R.D., Chanayem N.S., Zacharisen M.C., et al. Safety of aprotinin use and re-use in pediatric cardiothoracic surgery. Circulation 106 suppl I (2002) I90-I94
23. Tweddell J.S., Berger S., Frommelt P.C., et al. Aprotinin improves outcome of single-ventricle palliation. Ann Thorac Surg 62 (1996) 1329-1336